BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics and pharmacodynamics of a high concentration of buprenorphine (Simbadol) in conscious horses after subcutaneous administration. 2021

Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California Davis, Davis, CA, USA.

OBJECTIVE To determine the pharmacokinetics and pharmacodynamics of high-concentration formulation of buprenorphine (1.8 mg mL-1; Simbadol) following subcutaneous (SC) administration in horses. METHODS Prospective, randomized, crossover trial. METHODS A group of six healthy adult horses weighing 521-602 kg. METHODS On three occasions, Simbadol (0.005 mg kg-1; treatment S5), (0.0025 mg kg-1; treatment S2.5) or saline (treatment SAL) were administered SC at least 7 days apart in random order. Electrical nociceptive threshold (ENT) measured on the neck region, physiologic variables, locomotor activity, degree of restlessness and presence of excitatory signs were measured at baseline and for up to 48 hours after injection. Blood was collected for pharmacokinetic analysis at the same time intervals and plasma buprenorphine concentration (Cp) measured using liquid chromatography-tandem mass spectrometry. RESULTS Buprenorphine was quantifiable in all horses from 15 minutes after administration up to 8-12 hours. ENT was significantly increased in treatment S2.5 compared with treatment SAL at 0.75-6 hours after treatment. Increase in locomotor activity and compulsive behavior were recorded in all horses after Simbadol, and degree of restlessness was significantly higher in treatment S5 than SAL for a sustained time. Gastrointestinal motility significantly decreased in all horses after Simbadol and returned to baseline by 16 hours after treatment. CONCLUSIONS In horses, SC Simbadol was rapidly absorbed and Cp decreased rapidly. Side effects commonly seen in horses after opioids were observed in both Simbadol treatments, but degree of opioid-induced excitement lasted significantly longer in treatment S5. Simbadol (0.0025 mg kg-1) SC has the potential to be used clinically to treat pain in horses. However, at this dose, duration of antinociceptive effects was not longer than that reported for conventional buprenorphine, and side effects, including reduction in gastrointestinal motility and increased locomotor activity, were documented.

UI MeSH Term Description Entries
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D010147 Pain Measurement Scales, questionnaires, tests, and other methods used to assess pain severity and duration in patients or experimental animals to aid in diagnosis, therapy, and physiological studies. Analgesia Tests,Analogue Pain Scale,Formalin Test,McGill Pain Questionnaire,Nociception Tests,Pain Assessment,Pain Intensity,Pain Severity,Tourniquet Pain Test,Visual Analogue Pain Scale,Analog Pain Scale,Assessment, Pain,McGill Pain Scale,Visual Analog Pain Scale,Analgesia Test,Analog Pain Scales,Analogue Pain Scales,Formalin Tests,Intensity, Pain,Measurement, Pain,Nociception Test,Pain Assessments,Pain Intensities,Pain Measurements,Pain Questionnaire, McGill,Pain Scale, Analog,Pain Scale, Analogue,Pain Scale, McGill,Pain Severities,Pain Test, Tourniquet,Questionnaire, McGill Pain,Scale, Analog Pain,Scale, Analogue Pain,Scale, McGill Pain,Severity, Pain,Test, Analgesia,Test, Formalin,Test, Nociception,Test, Tourniquet Pain,Tests, Nociception,Tourniquet Pain Tests
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002047 Buprenorphine A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. 6029-M,Buprenex,Buprenorphine Hydrochloride,Buprex,Prefin,RX-6029-M,Subutex,Temgesic,Temgésic,6029 M,6029M,Hydrochloride, Buprenorphine,RX 6029 M,RX6029M
D006736 Horses Large, hoofed mammals of the family EQUIDAE. Horses are active day and night with most of the day spent seeking and consuming food. Feeding peaks occur in the early morning and late afternoon, and there are several daily periods of rest. Equus caballus,Equus przewalskii,Horse, Domestic,Domestic Horse,Domestic Horses,Horse,Horses, Domestic
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs.
July 2021, Veterinary anaesthesia and analgesia,
Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
Thermal antinociception after buccal administration of a high-concentration formulation of buprenorphine (Simbadol) at 0.24 mg kg-1 in conscious cats.
September 2018, Veterinary anaesthesia and analgesia,
Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
Pharmacokinetics and pharmacodynamics of meperidine after intramuscular and subcutaneous administration in horses.
February 2021, Veterinary surgery : VS,
Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
Pharmacokinetics, pharmacodynamics and antinociceptive effects of buprenorphine following transdermal administration to horses.
May 2024, Veterinary anaesthesia and analgesia,
Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.
August 1998, Journal of clinical pharmacology,
Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats.
January 2017, PloS one,
Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses.
August 2015, Journal of veterinary pharmacology and therapeutics,
Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
[Pharmacokinetics of buprenorphine in subcutaneous administration].
November 1995, Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS,
Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas.
March 2017, American journal of veterinary research,
Harriet Flynn, and Alessia Cenani, and Robert J Brosnan, and Heather K DiMaio Knych, and Antonio J de Araujo Aguiar
Pharmacokinetics and pharmacodynamics of furosemide after oral administration to horses.
January 2004, Journal of veterinary internal medicine,
Copied contents to your clipboard!